Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716133 | 0.92 | CYP3A4 (0.44) | MAP3K8CYP3A4SLC40A1BRAFCYP2C9 | |
| SCHEMBL14716094 | 0.91 | CYP3A4 (0.47) | MAP3K8CYP3A4SLC40A1BRAFCYP2C9 | |
| SCHEMBL14716131 | 0.86 | BRAF (0.43) | CYP3A4SLC40A1BRAFERBB2HSP90AA1 | |
| SCHEMBL14716229 | 0.86 | CYP2C9 (0.41) | MAP3K8CYP3A4SLC40A1BRAFCYP2C9 | |
| SCHEMBL14716460 | 0.84 | BRAF (0.43) | CYP3A4SLC40A1BRAFCYP2C9ERBB2 | |
| SCHEMBL14716227 | 0.84 | SLC40A1 (0.47) | CYP3A4SLC40A1BRAFERBB2HSP90AA1 | |
| SCHEMBL14716333 | 0.83 | BRAF (0.47) | CYP3A4BRAFCYP2C9 | |
| SCHEMBL14715959 | 0.83 | CYP3A4 (0.51) | CYP3A4SLC40A1BRAFCYP2C9LMNA | |
| SCHEMBL14715965 | 0.80 | MAP3K8 (0.41) | MAP3K8CYP2C9HSD17B1HSD17B2PIK3CA | |
| SCHEMBL14829481 | 0.79 | HSD17B14 (0.39) | CYP3A4CYP2C9HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | claimed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | claimed |
| EP-2747767-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-02 | — | — | EP | claimed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | claimed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170340630-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9572808-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2747767-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | MAP3K8 63/4885CYP3A4 646/4885SLC40A1 4351/4885 |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, BRAF, CHEK1 | MAP3K8 63/4885CYP3A4 646/4885SLC40A1 4351/4885 |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | MAP3K8 63/4885CYP3A4 646/4885SLC40A1 4351/4885 |
| US-20170340630-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | MAP3K8 63/4885CYP3A4 646/4885SLC40A1 4351/4885 |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, CHEK1, CHEK2 | MAP3K8 58/4885CYP3A4 735/4885SLC40A1 4312/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | MAP3K8 20/4885CYP3A4 1267/4885SLC40A1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.